Summary:
We are currently conducting a multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes.
Qualified Participants Must:
Be 18 years of age or older
Have untreated type 2 diabetes
Qualified Participants May Receive:
Up to $1,000 paid to qualified participants.